指南与共识胸部肿瘤泌尿男性生殖肿瘤骨软组织肉瘤与黑色素瘤

免疫改良实体瘤疗效评价标准(imRECIST):优化癌症免疫治疗临床获益评估的指南

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
指南 / 共识 · J Clin Oncol · 2018-01-17

基于非小细胞肺癌、转移性尿路上皮癌、肾细胞癌和黑色素瘤的atezolizumab临床试验数据,评估imRECIST与RECIST v1.1的差异。imRECIST允许疾病进展后最佳总体缓解,并调整进展定义;其最佳总体缓解提高1%至2%,疾病控制率提高8%至13%,中位无进展生存期延长0.5至1.5个月。imRECIST无进展生存期延长与总生存期延长或相似相关,但仅新病灶出现的进展与总生存期无关。

要点

  • imRECIST较RECIST v1.1提高最佳总体缓解1%至2%、疾病控制率8%至13%,中位PFS延长0.5至1.5个月。
  • imRECIST允许靶病灶进展后逆转,可能更好识别总生存获益患者。
  • 仅新病灶出现定义的进展与总生存期无关,需谨慎解读。

核心结论

  • imRECIST允许靶病灶从进展后逆转,可能更好识别免疫治疗的总生存获益患者。
  • 仅新病灶出现定义的进展与总生存期无关,需进一步修改影像学标准。

研究设计与样本

  • 基于非小细胞肺癌、转移性尿路上皮癌、肾细胞癌和黑色素瘤的atezolizumab临床试验数据评估imRECIST。
  • imRECIST与RECIST v1.1的修改包括允许疾病进展后最佳总体缓解,以及新病灶和非靶病灶的进展定义变化。

主要发现

  • imRECIST较RECIST v1.1最佳总体缓解提高1%至2%,疾病控制率提高8%至13%,中位无进展生存期延长0.5至1.5个月。
  • imRECIST无进展生存期延长与总生存期延长或相似相关。
  • 出现新病灶但无靶病灶进展的患者总生存期与RECIST v1.1靶病灶进展患者相似或更短。
  • 出现靶病灶先增大后缩小(spike模式)的患者不常见,但总生存期长于无靶病灶逆转的患者。

关键数值与推荐

  • imRECIST允许疾病进展后最佳总体缓解,并修改新病灶和非靶病灶的进展定义。
  • imRECIST无进展生存期不将初始进展计为事件,若后续扫描显示疾病控制。

临床怎么用

  • 在免疫治疗疗效评估中,可考虑采用imRECIST以更全面捕捉临床获益。
  • 对于仅新病灶出现的进展,应谨慎判断,因其与总生存期无关。

局限性

  • 数据来源于atezolizumab在四种肿瘤类型的临床试验,结论可能不适用于其他免疫治疗药物或瘤种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1.1 included allowance for best overall response after progressive disease (PD) and changes in PD definitions per new lesions (NLs) and nontarget lesions. imRECIST progression-free survival (PFS) did not count initial PD as an event if the subsequent scan showed disease control. OS was evaluated using conditional landmarks in patients whose PFS differed by imRECIST versus RECIST v1.1. Results The best overall response was 1% to 2% greater, the disease control rate was 8% to 13% greater, and the median PFS was 0.5 to 1.5 months longer per imRECIST versus RECIST v1.1. Extension of imRECIST PFS versus RECIST v1.1 PFS was associated with longer or similar OS. Patterns of progression analysis revealed that patients who developed NLs without target lesion (TL) progression had a similar or shorter OS compared with patients with RECIST v1.1 TL progression. Patients infrequently experienced a spike pattern (TLs increase, then decrease) but had longer OS than patients without TL reversion. Conclusion Evaluation of PFS and patterns of response and progression revealed that allowance for TL reversion from PD per imRECIST may better identify patients with OS benefit. Progression defined by the isolated appearance of NLs, however, is not associated with longer OS. These results may inform additional modifications to radiographic criteria (including imRECIST) to better reflect efficacy with CIT agents.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hodi FS, Ballinger M, Lyons B, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018. PMID: 29341833. doi:10.1200/JCO.2017.75.1644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。